Kinsale Capital Group Inc. Purchases 1,569 Shares of Amgen Inc. $AMGN

Kinsale Capital Group Inc. grew its position in Amgen Inc. (NASDAQ:AMGN) by 4.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 35,762 shares of the medical research company’s stock after buying an additional 1,569 shares during the quarter. Amgen accounts for 1.9% of Kinsale Capital Group Inc.’s holdings, making the stock its 16th largest holding. Kinsale Capital Group Inc.’s holdings in Amgen were worth $11,705,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in AMGN. Anfield Capital Management LLC lifted its holdings in shares of Amgen by 1,000.0% in the 4th quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock worth $25,000 after buying an additional 70 shares during the period. Dogwood Wealth Management LLC lifted its holdings in shares of Amgen by 275.0% in the 4th quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock worth $25,000 after buying an additional 55 shares during the period. Board of the Pension Protection Fund purchased a new stake in shares of Amgen in the 4th quarter worth $26,000. Manning & Napier Advisors LLC lifted its holdings in shares of Amgen by 49.2% in the 4th quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock worth $32,000 after buying an additional 32 shares during the period. Finally, Olistico Wealth LLC purchased a new stake in shares of Amgen in the 4th quarter worth $33,000. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Amgen Price Performance

AMGN opened at $326.31 on Friday. The business’s 50-day moving average is $349.17 and its two-hundred day moving average is $342.99. Amgen Inc. has a 1 year low of $267.73 and a 1 year high of $391.29. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01. The firm has a market capitalization of $176.10 billion, a PE ratio of 22.71, a price-to-earnings-growth ratio of 3.28 and a beta of 0.44.

Amgen (NASDAQ:AMGN) last posted its earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The company had revenue of $8.62 billion for the quarter, compared to analyst estimates of $8.58 billion. During the same quarter in the previous year, the firm earned $4.90 earnings per share. The firm’s quarterly revenue was up 5.8% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Research analysts anticipate that Amgen Inc. will post 22.37 earnings per share for the current fiscal year.

Amgen Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be paid a $2.52 dividend. This represents a $10.08 annualized dividend and a yield of 3.1%. The ex-dividend date is Friday, May 15th. Amgen’s payout ratio is 70.15%.

Insider Transactions at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of Amgen stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $323.73, for a total value of $400,454.01. Following the transaction, the senior vice president owned 7,009 shares in the company, valued at $2,269,023.57. The trade was a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.85% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on AMGN. Canaccord Genuity Group began coverage on Amgen in a report on Monday, April 20th. They issued a “hold” rating and a $366.00 target price for the company. Freedom Capital upgraded Amgen from a “hold” rating to a “strong-buy” rating in a report on Thursday, May 7th. Royal Bank Of Canada upped their target price on Amgen from $360.00 to $370.00 and gave the stock an “outperform” rating in a report on Tuesday, April 7th. Wells Fargo & Company upped their target price on Amgen from $375.00 to $390.00 and gave the stock an “equal weight” rating in a report on Thursday, March 19th. Finally, Cantor Fitzgerald reiterated a “neutral” rating and issued a $350.00 target price on shares of Amgen in a report on Wednesday, April 8th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, fourteen have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $356.15.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.